InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Enters Acquisition Agreement to Acquire Biodefense Vaccine Developer
April 2, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive arrangement agreement to acquire Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF). Appili is a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. According to the agreement, Adivir Inc., a wholly owned subsidiary of Aditxt, […]
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Acquisition Target Reports Increased Product Sales, Ongoing Revenue Growth
March 27, 2024
Aditxt (NASDAQ: ADTX) previously entered into a definitive agreement to acquire Evofem Biosciences Inc. (OTCQB: EVFM), which is believed to represent a compelling opportunity to accelerate Evofem’s growth trajectory, as a subsidiary of Aditxt, into a multi-product women’s health franchise. Today Evofem, the company behind Phexxi(R) (lactic acid, citric acid and potassium bitartrate) vaginal gel, […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Potential Acquisition Releases FY 2023 Preliminary Financial Report
February 1, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, entered into a definitive agreement with Evofem Biosciences Inc. (OTCQB: EVFM) late last year, and Evofem is reporting its preliminary financial results for 2023, which include record net sales of Phexxi(R), its hormone-free contraceptive gel. According to the report, Phexxi is seeing a […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Acquires Proprietary EEG Portfolio
January 30, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has announced its acquisition of a portfolio of electroencephalography “EEG” brain monitoring technologies and devices formerly owned by Brain Scientific, Inc. The products targeting the neurology monitoring market will be essential in shaping its dynamic landscape for neurological care. “This transaction […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX), Subsidiary Pearsanta Announce Acquisition of MDNA Life Sciences Inc.’s Mitomic(TM) Testing Platform
January 8, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, and its subsidiary Pearsanta Inc., have announced the acquisition of MDNA Life Sciences Inc.’s (“MDNA”) proprietary, early-disease and cancer-detection platform. According to the announcement, the acquisition “reinforces Pearsanta’s dedication to enhancing patient outcomes through early-disease detection and the power of precision diagnostics.” […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Secures $6M in Private Placement
January 5, 2024
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, announced that it has closed its private placement for the purchase and sale of an aggregate of 1,237,114 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.85 per […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains NASDAQ Compliance, Announces $6M Private Placement
January 2, 2024
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has regained compliance with NASDAQ’s minimum stockholders’ equity requirement. The company was notified by NASDAQ regarding the compliance issues, which is subject to a mandatory panel monitor until Dec. 29, 2024. In addition, the company announced that it has entered into definitive […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Definitive Agreement to Acquire Evofem Biosciences Inc.
December 12, 2023
Aditxt (NASDAQ: ADTX), a company dedicated to discovering, developing and deploying promising health innovations, has signed a definitive agreement with Evofem Biosciences Inc. (OTCQB: EVFM), a pioneer in women’s health. The agreement outlines plans for Aditxt to acquire Evofem in a transaction involving the issuance of a combination of common stock and preferred stock as well […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Participation at 8th Annual Dawson James Conference
October 6, 2023
Aditxt (NASDAQ: ADTX) is an innovation activation company focused on the discovery, development and deployment of technologies that monitor and modulate the immune system. The company today announced that it will present at the 8th Annual Dawson James Conference on Thursday, Oct. 12, 2023, at the Wyndam Grand Jupiter at Harbourside Place in Jupiter, Florida. […]
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Pearsanta Appoints Ernie Lee as CEO to Drive Launch of Test2Treat.me Platform
October 5, 2023
Aditxt (NASDAQ: ADTX) is a global innovation activation company focused on the discovery, development and deployment of technologies that monitor and modulate the immune system. The company today announced that it has appointed Ernie Lee to serve as the chief executive officer of its wholly owned subsidiary Pearsanta Inc. The appointment intends to accelerate the […]
Dawson James Small Cap Growth Conference: Exploring a Changing World of Investment Opportunities
September 26, 2023
Capital marketers, insurance and wealth management experts, investment bankers, individual investors, and research analysts, are invited to attend the Dawson James Small Cap Growth Conference to be held in Wyndham Grand Harborside Jupiter, Jupiter, FL, October 12, 2023. The distinguished conference serves as a hallmark in the financial world, featuring important management experts slated to […]
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
September 21, 2023
JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand Hotel in Jupiter, FL. Dawson James’ flagship Small Cap Growth Conference brings together senior leadership from […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Exec to Present at Upcoming H.C. Wainwright Global Investment Conference
September 8, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, will be participating in the 25th annual H.C. Wainwright Global Investment Conference; the premier event is scheduled for Sept. 11–13, 2023, in New York City. According to the announcement, Aditxt chair, cofounder and CEO Amro Albanna […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on $10M Private Placement
September 7, 2023
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has closed on its previously announced private placement. The placement was comprised of the purchase and sale of one million shares of common stock (or prefunded warrants in lieu thereof) at a purchase price of $10 […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Enter $10M Private Placement Agreements
September 1, 2023
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has entered into definitive agreements for the purchase and sale of common stock. According to the announcement, the private placements comprise one million shares of common stock (or prefunded warrant in lieu thereof) sold at $10 […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Issues Planned Strategy for Achieving Commercial Scale, Updated Release on 1-for-40 Reverse Split
August 18, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate the immune system, announced an important update regarding its innovation programs and strategic M&A initiatives. The shareholder update provides the company’s planned strategy for achieving commercial scale. “Aditxt takes a stakeholder-driven approach to […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Effect 1-for-40 Reverse Stock Split
August 17, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has announced that it will effect a 1-for-40 reverse split of its common stock effective as of 9:30 a.m. Eastern Time on Aug. 18, 2023. Commencing with the opening of trading on the Nasdaq Capital Market […]
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Pearsanta Inc. Enters LOI to Acquire Natural State Laboratories and Natural State Genomics
June 20, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, today announced the signing of an exclusive non-binding letter of intent (“LOI”) by its wholly owned subsidiary, Pearsanta(TM) Inc., to acquire both Natural State Laboratories LLC (“NSL”) and Natural State Genomics LLC (“NSG”) (collectively, “Natural State […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Inks Stiff Person Syndrome Clinical Trial Agreement with Mayo Clinic
May 5, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, and its subsidiary Adimune(TM) Inc. announced a clinical trial agreement with Mayo Clinic. The clinical trial, which is designed to advance clinical studies targeting autoimmune diseases of the central nervous system (“CNS”), is expected to begin this […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on $1.9M Registered Direct Offering
April 25, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced that it has closed on its previously announced registered direct offering. The company transacted the closing with a single healthcare-focused institutional investor; the closing consisted of the purchase and sale of 1,585,350 shares of common stock […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Registered Direct Offering Expected to Total $1.9M
April 21, 2023
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has entered into a definitive agreement. The company announced a registered direct offering totaling $1.9 million; the agreement is with a single healthcare-focused institutional investor and includes the purchase and sale of 1,585,350 shares of common […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Inks Asset Purchase Agreement for 50% Ownership of Global Response Aid
April 20, 2023
Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has signed an asset purchase agreement with Cellvera Ltd. According to the announcement, the agreement gives Aditxt a 50% ownership in G Response Aid FZE; the remaining 50% ownership belongs to global logistics leader Agility Inc. Calling […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Shareholder Update on Major Programs, M&A Plans
April 17, 2023
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has released a shareholder update outlining its three innovation programs and strategic M&A initiatives. The update notes that subsidiary Pearsanta submitted a bid to acquire substantially all assets of Lucira Health Inc., including Lucira Connect and […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Veteran of Media Industry as Chief Content, Engagement Officer
March 8, 2023
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has announced a new chief content and engagement officer. Maureen Connolly, an award-winning content strategic and audience builder, will step into the position. According to the announcement, Connolly has 20-plus years of experience in the health, […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Retains Top Banking Firm to Support Growth, Revenue-Generating Strategy
March 3, 2023
Aditxt Inc. (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, announced that it is working with Riverside Management Group LLC, a merchant banking firm providing investment banking advisory services; RMG will be supporting Aditxt’s strategic growth and revenue generating plans for its subsidiary Pearsanta Inc., […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms US-Based Subsidiary with Focus to Expand Innovation Platforms
February 14, 2023
Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the formation of a U.S.-based wholly owned subsidiary, Pearsanta Inc. The move intends to accelerate the expansion of Aditxt’s second program, AditxtScore(TM), through future strategic revenue and growth-oriented transactions. According to the update, […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Reaches Pivotal Milestone to Advance ADI (TM) Technology
January 20, 2023
Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD, Ph.D, a 30-year veteran of the pharmaceutical industry, as its chairman and CEO. “Dr. Kapp will be tasked with leading and developing the ADI(TM) immune modulation technology and ADI(TM)-100, Aditxt’s unique and potent antigen-specific immunotherapeutic […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Dedicated to New Era of Precision Medicine
January 11, 2023
Aditxt (NASDAQ: ADTX), a biotech innovation company, is developing and commercializing technologies with a focus on monitoring and modulating, mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. “In late October 2022, Aditxt announced the creation of its Adimune(TM) program. At the same time, Aditxt announced that Adimune initiated the […]
Aditxt, Inc. (NASDAQ: ADTX) Bolsters Goal to Conduct First-In-Human Clinical Trial Evaluating ADI(TM) Tech with Formation of Adimune, Inc. Subsidiary; Appoints Industry Veteran as Subsidiary Chairman and CEO
January 10, 2023
Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, on January 3, 2023 announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc. (“Adimune(TM)”). The company also announced the appointment of Dr. Joachim-Friedrich Kapp, M.D., Ph.D., as the CEO of Adimune(TM) and […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms Subsidiary with Focus on Immune Modulation Therapies
January 3, 2023
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced the formation of a U.S.-based subsidiary Adimune Inc. (“Adimune(TM)”) and its plans towards submission of a clinical trial application (“CTA”) for its immunotherapeutic technology drug candidate, ADI(TM)-100. The CTA […]
Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis
December 28, 2022
Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is focused on mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. These technologies are being developed to retrain the immune system to induce tolerance, to address, among other […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Equity Research Reports
November 28, 2022
Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, was featured in recent equity research reports published by H.C. Wainwright & Co. Titled “Personalizing Precision Immunological Therapy; Initiating at Buy and $4 PT” and “3Q22 Financial Results Reported; Reiterate Buy,” the publications discuss […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Key Milestone in Advancing Adimune(TM) Program
October 21, 2022
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced that its program Adimune(TM) has initiated the GMP manufacturing of drug candidate ADI(TM)-100 as a key milestone toward its goal to begin first-in-human trials during the second half of […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Announces Publication of Innovative Mathematical Model
October 12, 2022
Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to SARS-CoV-2 in a peer-reviewed research paper in the Journal of Theoretical Biology. The publication, titled […]
InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Featured in FedEx Video Presentation
October 7, 2022
Aditxt (NASDAQ: ADTX), a biotech innovation company, has announced that its AditxtScore(TM) is featured by FedEx in a video presentation that showcases the various ways in which both companies are playing critical roles in a challenging environment that includes the nation’s response to COVID-19. In the clip, the Aditxt team provides a virtual tour of […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
September 29, 2022
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced its receipt of confirmation from the Nasdaq Stock Market LLC Hearing Panel that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Issues Corporate Update Following Reverse Stock Split, Closing of $20M Public Offering
September 27, 2022
Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. The company today provided shareholders with a corporate update following the completion of a reverse stock split and closing of a previously announced $20 million public offering. “Aditxt’s key to success is multifaceted and tied […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on Recently Announced $20M Public Offering
September 21, 2022
Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has closed on its recent public offering. The offering was comprised of 3,333,333 shares of common stock or common stock equivalents; the offering also included warrants to purchase up to 3,333,333 shares of common stock. The […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Pricing of Public Offering
September 16, 2022
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has released the pricing of its public offering. The offering consists of 3,333,333 shares of its common stock (or common stock equivalents in lieu thereof) along with warrants to purchase up to 3,333,333 additional shares […]
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Looking to Solve Medical Challenge in Immune Responses
August 12, 2022
Aditxt (NASDAQ: ADTX) has sought to address a medical conundrum: approximately 50% of all transplanted organs are rejected by the host’s body within 10-12 years despite a wide array of medical innovations in recent years. This highlights the critical need for a practical, cost-effective solution to harmful immune responses. Aditxt is looking to solve this […]